Retour

Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference

News Conference Calls/ Webcasts

BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Doug Treco, Ph.D., CEO and Chairman of Inozyme, will participate in a fireside chat at the Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 from 6:40-7:10pm ET / 3:40-4:10pm PT.

GlobeNewswire Inc. • 08/05/2024 à 14:30:00
Inozyme Pharma, Inc. Common Stock
Address: 321 SUMMER STREET
Postal Code: 02210
City: BOSTON
State: MA
Phone Number: 857-330-4340
Website: https://www.inozyme.com
Status: Active
Company Info

Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.

List Date2020-07-24
MarketStocks
LocalUS
Primary ExchangeXNAS
TypeCS
Currency NameUSD
CIK0001693011
Composite figiBBG00J7QJMC1
Share Class figiBBG00J7QJMD0
Market Cap284,535,341 USD
SIC Code2834
SIC DescriptionPHARMACEUTICAL PREPARATIONS
Total Employees59
Share Class Shares Outstanding61860000
Weighted Shares Outstanding61855509
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
17-05
16-05
15-05
14-05
13-05
Last
4.605
4.721
4.74
4.68
4.425
Variance
-2.48%
-0.84%
2.38%
6.03%
-0.67%
Open
4.722
4.761
4.63
4.414
4.455
Highest
4.773
4.864
4.81
4.715
4.71
Lowest
4.735
4.761
4.796
4.702
4.706
History
PeriodVarhighestlowest
1 week
3.37%
4.71
4.702
1 month
2.17%
4.545
4.415
3 month
-17.47%
5.988
4.415
6 month
41.26%
3.95
3.26
1 year
-28.05%
6.67
2.689
3 year
-70.39%
16.1
0.991
5 year
-77.86%
21.5
0.991
10 year
-77.86%
21.5
0.991
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-09 2023-08-08 2023-11-07 UNPUB
Assets 141,796,000 150,929,000 205,702,000 UNPUB
Current Assets 134,148,000 143,588,000 200,856,000 UNPUB
Current Liabilities 12,581,000 12,081,000 12,275,000 UNPUB
Equity 103,347,000 105,593,000 160,213,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 103,347,000 105,593,000 160,213,000 UNPUB
Liabilities 38,449,000 45,336,000 45,489,000 UNPUB
Liabilities And Equity 141,796,000 150,929,000 205,702,000 UNPUB
Noncurrent Assets 7,648,000 7,341,000 4,846,000 UNPUB
Noncurrent Liabilities 25,868,000 33,255,000 33,214,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-09 2023-08-08 2023-11-07 UNPUB
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow 16,090,000 -8,233,000 6,232,000 UNPUB
Net Cash Flow, Continuing 16,090,000 -8,233,000 6,232,000 UNPUB
Net Cash Flow From Financing Activities 20,096,000 23,642,000 69,715,000 UNPUB
Net Cash Flow From Financing Activities, Continuing 20,096,000 23,642,000 69,715,000 UNPUB
Net Cash Flow From Investing Activities 13,766,000 -16,327,000 -44,615,000 UNPUB
Net Cash Flow From Investing Activities, Continuing 13,766,000 -16,327,000 -44,615,000 UNPUB
Net Cash Flow From Operating Activities -17,772,000 -15,548,000 -18,868,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -17,772,000 -15,548,000 -18,868,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-09 2023-08-08 2023-11-07 UNPUB
Comprehensive Income/Loss -17,235,000 -15,496,000 -16,767,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -17,235,000 -15,496,000 -16,767,000 UNPUB
Other Comprehensive Income/Loss 169,000 87,000 -129,000 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-09 2023-08-08 2023-11-07 UNPUB
Basic Earnings Per Share 0 0 0 UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share 0 0 0 UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -17,404,000 -15,583,000 -16,638,000 UNPUB
Income/Loss From Continuing Operations Before Tax -17,404,000 -15,583,000 -16,638,000 UNPUB
Income Tax Expense/Benefit UNPUB UNPUB UNPUB UNPUB
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -17,404,000 -15,583,000 -16,638,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -17,404,000 -15,583,000 -16,638,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -17,404,000 -15,583,000 -16,638,000 UNPUB
Operating Expenses 18,369,000 16,394,000 18,074,000 UNPUB
Operating Income/Loss -18,369,000 -16,394,000 -18,074,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 0 0 0 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-10 2022-08-15 2022-11-10 2023-03-22
Assets 108,931,000 161,989,000 154,021,000 139,195,000
Current Assets 100,583,000 153,748,000 145,926,000 131,393,000
Current Liabilities 12,260,000 10,573,000 13,133,000 14,715,000
Equity 94,229,000 149,176,000 134,780,000 118,394,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 94,229,000 149,176,000 134,780,000 118,394,000
Liabilities 14,702,000 12,813,000 19,241,000 20,801,000
Liabilities And Equity 108,931,000 161,989,000 154,021,000 139,195,000
Noncurrent Assets 8,348,000 8,241,000 8,095,000 7,802,000
Noncurrent Liabilities 0 0 6,108,000 6,086,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-10 2022-08-15 2022-11-10 2023-03-22
Exchange Gains/Losses -15,000 UNPUB UNPUB UNPUB
Net Cash Flow 8,642,000 30,720,000 -18,556,000 9,624,000
Net Cash Flow, Continuing 8,657,000 30,705,000 -18,556,000 9,624,000
Net Cash Flow From Financing Activities 240,000 68,333,000 4,215,000 72,788,000
Net Cash Flow From Financing Activities, Continuing 240,000 68,333,000 4,215,000 72,788,000
Net Cash Flow From Investing Activities 22,562,000 -22,926,000 -8,257,000 -5,403,000
Net Cash Flow From Investing Activities, Continuing 22,562,000 -22,926,000 -8,257,000 -5,403,000
Net Cash Flow From Operating Activities -14,160,000 -14,687,000 -14,514,000 -57,761,000
Net Cash Flow From Operating Activities, Continuing -14,160,000 -14,687,000 -14,514,000 -57,761,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-10 2022-08-15 2022-11-10 2023-03-22
Comprehensive Income/Loss -16,884,000 -15,261,000 -16,452,000 -67,284,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -17,031,000 -15,529,000 -16,452,000 -67,284,000
Other Comprehensive Income/Loss -147,000 -268,000 -80,000 -223,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-10 2022-08-15 2022-11-10 2023-03-22
Basic Earnings Per Share -1 0 0 -2
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share -1 0 0 -2
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -16,884,000 -15,261,000 -16,372,000 -67,061,000
Income/Loss From Continuing Operations Before Tax -16,884,000 -15,261,000 -16,372,000 -67,061,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 0
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -16,884,000 -15,261,000 -16,372,000 -67,061,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -16,884,000 -15,261,000 -16,372,000 -67,061,000
Net Income/Loss Available To Common Stockholders, Basic -16,884,000 -15,261,000 -16,372,000 -67,061,000
Operating Expenses 16,839,000 15,391,000 16,912,000 68,675,000
Operating Income/Loss -16,839,000 -15,391,000 -16,912,000 -68,675,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-12 2021-08-11 2021-11-09 2022-03-15
Assets 158,915,000 148,259,000 137,746,000 123,541,000
Current Assets 148,041,000 140,962,000 130,579,000 115,342,000
Current Liabilities 6,832,000 6,972,000 8,943,000 11,633,000
Equity 148,889,000 138,274,000 125,974,000 109,268,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 148,889,000 138,274,000 125,974,000 109,268,000
Liabilities 10,026,000 9,985,000 11,772,000 14,273,000
Liabilities And Equity 158,915,000 148,259,000 137,746,000 123,541,000
Noncurrent Assets 10,874,000 7,297,000 7,167,000 8,199,000
Noncurrent Liabilities 0 0 2,829,000 2,640,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-12 2021-08-11 2021-11-09 2022-03-15
Exchange Gains/Losses UNPUB UNPUB UNPUB 24,000
Net Cash Flow -11,554,000 9,753,000 999,000 -4,724,000
Net Cash Flow, Continuing -11,554,000 9,753,000 999,000 -4,748,000
Net Cash Flow From Financing Activities 249,000 112,000 237,000 609,000
Net Cash Flow From Financing Activities, Continuing 249,000 112,000 237,000 609,000
Net Cash Flow From Investing Activities 573,000 19,674,000 13,062,000 42,796,000
Net Cash Flow From Investing Activities, Continuing 573,000 19,674,000 13,062,000 42,796,000
Net Cash Flow From Operating Activities -12,376,000 -10,033,000 -12,300,000 -48,153,000
Net Cash Flow From Operating Activities, Continuing -12,376,000 -10,033,000 -12,300,000 -48,153,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-12 2021-08-11 2021-11-09 2022-03-15
Comprehensive Income/Loss -11,050,000 -12,540,000 -14,295,000 -56,608,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -11,040,000 -12,534,000 -14,295,000 -56,608,000
Other Comprehensive Income/Loss 10,000 6,000 -15,000 16,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-12 2021-08-11 2021-11-09 2022-03-15
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax -11,050,000 -12,540,000 -14,280,000 -56,624,000
Income/Loss From Continuing Operations Before Tax -11,050,000 -12,540,000 -14,280,000 -56,624,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 0
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss -11,050,000 -12,540,000 -14,280,000 -56,624,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -11,050,000 -12,540,000 -14,280,000 -56,624,000
Net Income/Loss Available To Common Stockholders, Basic -11,050,000 -12,540,000 -14,280,000 -56,624,000
Operating Expenses 10,972,000 12,655,000 14,262,000 56,646,000
Operating Income/Loss -10,972,000 -12,655,000 -14,262,000 -56,646,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 0 0 0 0
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2020-11-12 2021-03-25
Assets UNPUB UNPUB 178,993,000 169,363,000
Current Assets UNPUB UNPUB 163,977,000 150,979,000
Current Liabilities UNPUB UNPUB 9,814,000 9,973,000
Equity UNPUB UNPUB 167,916,000 158,103,000
Equity Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Equity Attributable To Parent UNPUB UNPUB 167,916,000 158,103,000
Liabilities UNPUB UNPUB 11,077,000 11,260,000
Liabilities And Equity UNPUB UNPUB 178,993,000 169,363,000
Noncurrent Assets UNPUB UNPUB 15,016,000 18,384,000
Noncurrent Liabilities UNPUB UNPUB 1,263,000 1,287,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2020-11-12 2021-03-25
Exchange Gains/Losses UNPUB UNPUB UNPUB UNPUB
Net Cash Flow UNPUB UNPUB 8,994,000 -3,341,000
Net Cash Flow, Continuing UNPUB UNPUB 8,994,000 -3,341,000
Net Cash Flow From Financing Activities UNPUB UNPUB 118,861,000 149,812,000
Net Cash Flow From Financing Activities, Continuing UNPUB UNPUB 118,861,000 149,812,000
Net Cash Flow From Investing Activities UNPUB UNPUB -99,666,000 -117,179,000
Net Cash Flow From Investing Activities, Continuing UNPUB UNPUB -99,666,000 -117,179,000
Net Cash Flow From Operating Activities UNPUB UNPUB -10,201,000 -35,974,000
Net Cash Flow From Operating Activities, Continuing UNPUB UNPUB -10,201,000 -35,974,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2020-11-12 2021-03-25
Comprehensive Income/Loss UNPUB UNPUB -28,108,000 -56,427,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB -28,108,000 -56,427,000
Other Comprehensive Income/Loss UNPUB UNPUB -13,000 -3,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date UNPUB UNPUB 2020-11-12 2021-03-25
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses UNPUB UNPUB UNPUB UNPUB
Cost Of Revenue UNPUB UNPUB UNPUB UNPUB
Costs And Expenses UNPUB UNPUB UNPUB UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit UNPUB UNPUB UNPUB UNPUB
Income/Loss From Continuing Operations After Tax UNPUB UNPUB -28,095,000 -56,424,000
Income/Loss From Continuing Operations Before Tax UNPUB UNPUB -28,095,000 -56,424,000
Income Tax Expense/Benefit UNPUB UNPUB UNPUB 0
Interest Expense, Operating UNPUB UNPUB UNPUB UNPUB
Net Income/Loss UNPUB UNPUB -28,095,000 -56,424,000
Net Income/Loss Attributable To Noncontrolling Interest UNPUB UNPUB 0 0
Net Income/Loss Attributable To Parent UNPUB UNPUB -28,095,000 -56,424,000
Net Income/Loss Available To Common Stockholders, Basic UNPUB UNPUB -28,095,000 -56,424,000
Operating Expenses UNPUB UNPUB 28,316,000 57,041,000
Operating Income/Loss UNPUB UNPUB -28,316,000 -57,041,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic UNPUB UNPUB 0 0
Preferred Stock Dividends And Other Adjustments UNPUB UNPUB 0 0
Revenues UNPUB UNPUB 0 0
Calendar
19 May 2024 (Time UTC) Actual Previous Consensus
★★★
15:30
United States
17 May 2024 (Time UTC) Actual Previous Consensus
★
15:30
United States
-17800.000
★
15:30
United States
-60000.000
★
15:30
United States
53700.000
★
15:30
United States
-135800.000
★★
15:30
United States
4400.000
★
15:30
United States
215400.000
★
15:30
United States
-31400.000
★
15:30
United States
62600.000
★
15:30
United States
1300.000
★
15:30
United States
-9700.000
★
15:30
United States
199600.000
★★
15:30
United States
★
15:30
United States
★
15:30
United States
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:INZY240517P00007500 OPASPS Put American 100 7.5 BATO 2024-05-17
O:INZY240517P00005000 OPASPS Put American 100 5 BATO 2024-05-17
O:INZY240517P00002500 OPASPS Put American 100 2.5 BATO 2024-05-17
O:INZY240517C00007500 OCASPS Call American 100 7.5 BATO 2024-05-17
O:INZY240517C00005000 OCASPS Call American 100 5 BATO 2024-05-17
O:INZY240517C00002500 OCASPS Call American 100 2.5 BATO 2024-05-17
O:INZY240517P00012500 OPASPS Put American 100 12.5 BATO 2024-05-17
O:INZY240517C00012500 OCASPS Call American 100 12.5 BATO 2024-05-17
O:INZY240517P00010000 OPASPS Put American 100 10 BATO 2024-05-17
O:INZY240517C00010000 OCASPS Call American 100 10 BATO 2024-05-17
O:INZY240419P00012500 OPASPS Put American 100 12.5 BATO 2024-04-19
O:INZY240419C00012500 OCASPS Call American 100 12.5 BATO 2024-04-19
O:INZY240419P00010000 OPASPS Put American 100 10 BATO 2024-04-19
O:INZY240419P00007500 OPASPS Put American 100 7.5 BATO 2024-04-19
O:INZY240419P00005000 OPASPS Put American 100 5 BATO 2024-04-19
O:INZY240419P00002500 OPASPS Put American 100 2.5 BATO 2024-04-19
O:INZY240419C00010000 OCASPS Call American 100 10 BATO 2024-04-19
O:INZY240419C00007500 OCASPS Call American 100 7.5 BATO 2024-04-19
O:INZY240419C00005000 OCASPS Call American 100 5 BATO 2024-04-19
O:INZY240419C00002500 OCASPS Call American 100 2.5 BATO 2024-04-19
O:INZY240315P00007500 OPASPS Put American 100 7.5 BATO 2024-03-15
O:INZY240315P00005000 OPASPS Put American 100 5 BATO 2024-03-15
O:INZY240315P00002500 OPASPS Put American 100 2.5 BATO 2024-03-15
O:INZY240315C00007500 OCASPS Call American 100 7.5 BATO 2024-03-15
O:INZY240315C00005000 OCASPS Call American 100 5 BATO 2024-03-15
O:INZY240315C00002500 OCASPS Call American 100 2.5 BATO 2024-03-15
O:INZY240315P00010000 OPASPS Put American 100 10 BATO 2024-03-15
O:INZY240315C00010000 OCASPS Call American 100 10 BATO 2024-03-15
O:INZY240216P00012500 OPASPS Put American 100 12.5 BATO 2024-02-16
O:INZY240216P00010000 OPASPS Put American 100 10 BATO 2024-02-16
O:INZY240216P00007500 OPASPS Put American 100 7.5 BATO 2024-02-16
O:INZY240216P00005000 OPASPS Put American 100 5 BATO 2024-02-16
O:INZY240216P00002500 OPASPS Put American 100 2.5 BATO 2024-02-16
O:INZY240216C00012500 OCASPS Call American 100 12.5 BATO 2024-02-16
O:INZY240216C00010000 OCASPS Call American 100 10 BATO 2024-02-16
O:INZY240216C00007500 OCASPS Call American 100 7.5 BATO 2024-02-16
O:INZY240216C00005000 OCASPS Call American 100 5 BATO 2024-02-16
O:INZY240216C00002500 OCASPS Call American 100 2.5 BATO 2024-02-16
O:INZY240119P00007500 OPASPS Put American 100 7.5 BATO 2024-01-19
O:INZY240119P00005000 OPASPS Put American 100 5 BATO 2024-01-19
O:INZY240119P00002500 OPASPS Put American 100 2.5 BATO 2024-01-19
O:INZY240119C00007500 OCASPS Call American 100 7.5 BATO 2024-01-19
O:INZY240119C00005000 OCASPS Call American 100 5 BATO 2024-01-19
O:INZY240119C00002500 OCASPS Call American 100 2.5 BATO 2024-01-19
O:INZY231215P00007500 OPASPS Put American 100 7.5 BATO 2023-12-15
O:INZY231215P00005000 OPASPS Put American 100 5 BATO 2023-12-15
O:INZY231215P00002500 OPASPS Put American 100 2.5 BATO 2023-12-15
O:INZY231215C00007500 OCASPS Call American 100 7.5 BATO 2023-12-15
O:INZY231215C00005000 OCASPS Call American 100 5 BATO 2023-12-15
O:INZY231215C00002500 OCASPS Call American 100 2.5 BATO 2023-12-15
O:INZY231117P00012500 OPASPS Put American 100 12.5 BATO 2023-11-17
O:INZY231117P00010000 OPASPS Put American 100 10 BATO 2023-11-17
O:INZY231117P00007500 OPASPS Put American 100 7.5 BATO 2023-11-17
O:INZY231117P00005000 OPASPS Put American 100 5 BATO 2023-11-17
O:INZY231117P00002500 OPASPS Put American 100 2.5 BATO 2023-11-17
O:INZY231117C00012500 OCASPS Call American 100 12.5 BATO 2023-11-17
O:INZY231117C00010000 OCASPS Call American 100 10 BATO 2023-11-17
O:INZY231117C00007500 OCASPS Call American 100 7.5 BATO 2023-11-17
O:INZY231117C00005000 OCASPS Call American 100 5 BATO 2023-11-17
O:INZY231117C00002500 OCASPS Call American 100 2.5 BATO 2023-11-17
O:INZY231020P00007500 OPASPS Put American 100 7.5 BATO 2023-10-20
O:INZY231020P00005000 OPASPS Put American 100 5 BATO 2023-10-20
O:INZY231020P00002500 OPASPS Put American 100 2.5 BATO 2023-10-20
O:INZY231020C00007500 OCASPS Call American 100 7.5 BATO 2023-10-20
O:INZY231020C00005000 OCASPS Call American 100 5 BATO 2023-10-20
O:INZY231020C00002500 OCASPS Call American 100 2.5 BATO 2023-10-20
O:INZY230915P00012500 OPASPS Put American 100 12.5 BATO 2023-09-15
O:INZY230915P00010000 OPASPS Put American 100 10 BATO 2023-09-15
O:INZY230915P00007500 OPASPS Put American 100 7.5 BATO 2023-09-15
O:INZY230915P00005000 OPASPS Put American 100 5 BATO 2023-09-15
O:INZY230915P00002500 OPASPS Put American 100 2.5 BATO 2023-09-15
O:INZY230915C00012500 OCASPS Call American 100 12.5 BATO 2023-09-15
O:INZY230915C00010000 OCASPS Call American 100 10 BATO 2023-09-15
O:INZY230915C00007500 OCASPS Call American 100 7.5 BATO 2023-09-15
O:INZY230915C00005000 OCASPS Call American 100 5 BATO 2023-09-15
O:INZY230915C00002500 OCASPS Call American 100 2.5 BATO 2023-09-15
O:INZY230818P00012500 OPASPS Put American 100 12.5 BATO 2023-08-18
O:INZY230818P00010000 OPASPS Put American 100 10 BATO 2023-08-18
O:INZY230818P00007500 OPASPS Put American 100 7.5 BATO 2023-08-18
O:INZY230818P00005000 OPASPS Put American 100 5 BATO 2023-08-18
O:INZY230818P00002500 OPASPS Put American 100 2.5 BATO 2023-08-18
O:INZY230818C00012500 OCASPS Call American 100 12.5 BATO 2023-08-18
O:INZY230818C00010000 OCASPS Call American 100 10 BATO 2023-08-18
O:INZY230818C00007500 OCASPS Call American 100 7.5 BATO 2023-08-18
O:INZY230818C00005000 OCASPS Call American 100 5 BATO 2023-08-18
O:INZY230818C00002500 OCASPS Call American 100 2.5 BATO 2023-08-18
News Stream
News Conference Calls/ Webcasts
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Doug Treco, Ph.D., CEO and Chairman of Inozyme, will participate in a fireside chat at the Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 from 6:40-7:10pm ET / 3:40-4:10pm PT.
GlobeNewswire Inc. • 1w ago
Stocks Earnings Releases and Operating Results
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
Inozyme reported financial results for the first quarter ended March 31, 2024 and provided business highlights.
GlobeNewswire Inc. • 1w ago
Stocks Changes in company's own shares
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Inozyme granted stock options to one new employee to purchase shares of the Company’s common stock as an inducement material to the new employee.
GlobeNewswire Inc. • 2w ago
News Clinical Study
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
- Favorable safety and immunogenicity profile in ABCC6 Deficiency, with clinical improvements in vascular pathology, visual function and patient reported outcomes (PROs) -
GlobeNewswire Inc. • 1mo ago
Management Management statements
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it granted stock options to three new employees to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan, as inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
GlobeNewswire Inc. • 1mo ago
Calendar Calendar of Events
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that Doug Treco, Ph.D., the company’s chief executive officer and chairman of the board, will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 from 10:15-10:55 a.m. ET.
GlobeNewswire Inc. • 1mo ago
stocks Product / Services Announcement
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
Inozyme announced that it will host a conference call and webcast on Monday, Apr. 8, 2024 at 8:00 a.m. ET.
GlobeNewswire Inc. • 1mo ago
News Product / Services Announcement
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
Inozyme announced that it will host a conference call and webcast on Monday, Apr. 8, 2024 at 8:00 a.m. ET.
GlobeNewswire Inc. • 1mo ago
Stocks Earnings Releases and Operating Results
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
– Topline data from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected in early April –
GlobeNewswire Inc. • 2mo ago
Calendar Calendar of Events
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference
- Douglas A. Treco, Ph.D., CEO and Chairman, to participate in panel discussion - - Douglas A. Treco, Ph.D., CEO and Chairman, to participate in panel discussion -
GlobeNewswire Inc. • 2mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT